AVXL | tickerfilter.com

Fundamental analysis

25%

Profitability 25%

Dept financing 5%

Liquidity 50%

Performance 25%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

12.34%

1 Month

39.09%

3 Months

121.13%

6 Months

192.77%

1 Year

26.74%

2 Year

53.92%

Key data

Stock price

$12.08

P/E Ratio

0.00

DAY RANGE

$11.81 - $13.26

EPS

$0.00

52 WEEK RANGE

$3.46 - $14.44

52 WEEK CHANGE

$34.91

MARKET CAP

510.469 M

YIELD

N/A

SHARES OUTSTANDING

84.796 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

11/25/2024

BETA

2.07

PUBLIC FLOAT

AVERAGE 10 VOLUME

$3,278,526

AVERAGE 30 VOLUME

$1,999,008

Company detail

CEO: Christopher U. Missling
Region: US
Website: anavex.com
Employees: 40
IPO year: -

Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

Anavex Life Sciences Corp. engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the. treatment of Alzheimer's disease. The company's drug candidate also comprises ANaVEX 3-71 which is. in Phase I clinical. trial for frontotemporal dementia and other dementia indications.

AVXL - ANAVEX LIFE SCIENCES CORP.